Trial Profile
Efficacy and safety of chidamide, bortezomib and dexamethasone combination in transplant-ineligible patients with relapsed/refractory multiple myeloma: a phase 2, single center, single arm study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 14 Jan 2017
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Tucidinostat (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 03 Jan 2017 New trial record